Ongoing trials of immune checkpoint blockade in acute myeloid leukemia
Data were compiled from ClinicalTrials.gov (https://clinicaltrials.gov) 7/2016.
| Type | Therapy | Primary Outcome | Inclusion | Clinicaltrials.gov Identifier |
|---|---|---|---|---|
| Phase 1 | Ipilimumab | Acute GVHD graft rejection Autoimmune reaction | Solid tumors, lymphoma and leukemia, including relapsed/refractory AML after allo-SCT | NCT00060372 |
| Phase 1 | Ipilimumab | Toxicity and immunologic response | Relapsed/refractory AML or CMML or high-risk MDS | NCT01757639 |
| Phase 1/1b | Ipilimumab or nivolumab | Toxicity and MTD | Relapsed leukemia, including AML, lymphoma and MM after allo-SCT | NCT01822509 |
| Phase 2 | Pidilizumab + DC vaccine | Toxicity | AML in CR before cell collection for DC generation | NCT01096602 |
| Phase 2 | Azacytidine + nivolumab | Response rate, overall survival | Relapsed AML and frontline elderly (>65 years) AML | NCT02397720 |
| Phase 2 | Idarubicin and cytarabine + nivolumab | Event-free survival | Induction in newly diagnosed AML <60 years | NCT02464657 |
| Phase 2 | Nivolumab | Recurrence-Free Survival | AML in remission | NCT02532231 |
allo-SCT, allogeneic stem cell transplantation; AML, acute myeloid leukemia; CMML, chronic myelomonocytic leukemia; CR, complete response; DC, dendritic cell; GVHD, graft versus host disease; MDS, myelodysplastic syndrome; MM, multiple myeloma.